| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| M Schmauss, B Diekamp, M Gerwe, A Schreiner, B Ibac. Does oral antipsychotic pre-treatment influence outcome of a switch to long-acting injectable risperidone in patients with schizophrenia? Pharmacopsychiatry. vol 43. issue 2. 2010-06-11. PMID:20131207. |
the objective of this open-label study was to evaluate treatment benefits of risperidone long-acting injectable (rlai) in patients with schizophrenia following direct transition from oral risperidone (ris) compared with transition from other oral second generation antipsychotics. |
2010-06-11 |
2023-08-12 |
Not clear |
| Jong-Hoon Kim, Min-Jung Ki. Association of adverse drug effects with subjective well-being in patients with schizophrenia receiving stable doses of risperidone. Clinical neuropharmacology. vol 32. issue 5. 2010-06-01. PMID:19620847. |
association of adverse drug effects with subjective well-being in patients with schizophrenia receiving stable doses of risperidone. |
2010-06-01 |
2023-08-12 |
Not clear |
| Jong-Hoon Kim, Min-Jung Ki. Association of adverse drug effects with subjective well-being in patients with schizophrenia receiving stable doses of risperidone. Clinical neuropharmacology. vol 32. issue 5. 2010-06-01. PMID:19620847. |
the purpose of the present study was to examine the association of adverse drug effects with subjective well-being in patients with schizophrenia receiving stable doses of risperidone. |
2010-06-01 |
2023-08-12 |
Not clear |
| Taro Kishi, Masatsugu Moriwaki, Tsuyoshi Kitajima, Kunihiro Kawashima, Tomo Okochi, Yasuhisa Fukuo, Osamu Furukawa, Hiroshi Naitoh, Kiyoshi Fujita, Nakao Iwat. Effect of aripiprazole, risperidone, and olanzapine on the acoustic startle response in Japanese chronic schizophrenia. Psychopharmacology. vol 209. issue 2. 2010-05-28. PMID:20177883. |
effect of aripiprazole, risperidone, and olanzapine on the acoustic startle response in japanese chronic schizophrenia. |
2010-05-28 |
2023-08-12 |
Not clear |
| Taro Kishi, Masatsugu Moriwaki, Tsuyoshi Kitajima, Kunihiro Kawashima, Tomo Okochi, Yasuhisa Fukuo, Osamu Furukawa, Hiroshi Naitoh, Kiyoshi Fujita, Nakao Iwat. Effect of aripiprazole, risperidone, and olanzapine on the acoustic startle response in Japanese chronic schizophrenia. Psychopharmacology. vol 209. issue 2. 2010-05-28. PMID:20177883. |
we investigated the influence on startle response in chronic schizophrenia in 20 patients with schizophrenia taking risperidone, 21 patients with schizophrenia taking olanzapine, and 20 patients with schizophrenia taking aripiprazole. |
2010-05-28 |
2023-08-12 |
Not clear |
| Nicolas M Furiak, Haya Ascher-Svanum, Robert W Klein, Lee J Smolen, Anthony H Lawson, Robert R Conley, Steven D Culle. Cost-effectiveness model comparing olanzapine and other oral atypical antipsychotics in the treatment of schizophrenia in the United States. Cost effectiveness and resource allocation : C/E. vol 7. 2010-05-20. PMID:19351408. |
this study compares the cost-effectiveness of oral olanzapine, oral risperidone (at generic cost, primary comparator), quetiapine, ziprasidone, and aripiprazole in the treatment of patients with schizophrenia from the perspective of third-party payers in the u.s. health care system. |
2010-05-20 |
2023-08-12 |
Not clear |
| J Peuskens, J M Olivares, J Pecenak, I Tuma, H Bij de Weg, L Eriksson, S Resseler, K Akhras, A Jacob. Treatment retention with risperidone long-acting injection: 24-month results from the Electronic Schizophrenia Treatment Adherence Registry (e-STAR) in six countries. Current medical research and opinion. vol 26. issue 3. 2010-05-20. PMID:20014981. |
treatment retention with risperidone long-acting injection: 24-month results from the electronic schizophrenia treatment adherence registry (e-star) in six countries. |
2010-05-20 |
2023-08-12 |
Not clear |
| J Peuskens, J M Olivares, J Pecenak, I Tuma, H Bij de Weg, L Eriksson, S Resseler, K Akhras, A Jacob. Treatment retention with risperidone long-acting injection: 24-month results from the Electronic Schizophrenia Treatment Adherence Registry (e-STAR) in six countries. Current medical research and opinion. vol 26. issue 3. 2010-05-20. PMID:20014981. |
to assess treatment retention on risperidone long-acting injection (rlai) and outcomes in schizophrenia patients for whom 24 months of follow-up data in the electronic schizophrenia treatment adherence registry (e-star) were available. |
2010-05-20 |
2023-08-12 |
Not clear |
| Clarissa Kripk. Risperidone vs. placebo for schizophrenia. American family physician. vol 81. issue 9. 2010-05-14. PMID:20433125. |
risperidone vs. placebo for schizophrenia. |
2010-05-14 |
2023-08-12 |
Not clear |
| Matej Kastelic, Jure Koprivsek, Blanka Kores Plesnicar, Alessandro Serretti, Laura Mandelli, Igor Locatelli, Iztok Grabnar, Vita Dolza. MDR1 gene polymorphisms and response to acute risperidone treatment. Progress in neuro-psychopharmacology & biological psychiatry. vol 34. issue 2. 2010-05-13. PMID:20060871. |
in the present study we investigated the influence of two common mdr1 polymorphisms on the improvement of psychopathological symptoms and occurrence of extrapyramidal side effects (eps) in slovenian schizophrenia patients acutely treated with risperidone. |
2010-05-13 |
2023-08-12 |
Not clear |
| Matej Kastelic, Jure Koprivsek, Blanka Kores Plesnicar, Alessandro Serretti, Laura Mandelli, Igor Locatelli, Iztok Grabnar, Vita Dolza. MDR1 gene polymorphisms and response to acute risperidone treatment. Progress in neuro-psychopharmacology & biological psychiatry. vol 34. issue 2. 2010-05-13. PMID:20060871. |
the present study does not suggest a major influence of mdr1 g2677t/a and c3435t polymorphisms on treatment response during short-term risperidone therapy in patients with schizophrenia or schizoaffective disorder. |
2010-05-13 |
2023-08-12 |
Not clear |
| Suwanna Arunpongpaisal, Manit Srisurapanont, Ronnachai Kongsakon, Khanogwan Kitiwattanagul, Umpaikanit Samanwongtha. Risperidone long-acting injection (RLAI): the 12-week efficacy and tolerability in Thai patients with chronic schizophrenia. Journal of the Medical Association of Thailand = Chotmaihet thangphaet. vol 93. issue 3. 2010-05-13. PMID:20420110. |
risperidone long-acting injection (rlai): the 12-week efficacy and tolerability in thai patients with chronic schizophrenia. |
2010-05-13 |
2023-08-12 |
Not clear |
| Suwanna Arunpongpaisal, Manit Srisurapanont, Ronnachai Kongsakon, Khanogwan Kitiwattanagul, Umpaikanit Samanwongtha. Risperidone long-acting injection (RLAI): the 12-week efficacy and tolerability in Thai patients with chronic schizophrenia. Journal of the Medical Association of Thailand = Chotmaihet thangphaet. vol 93. issue 3. 2010-05-13. PMID:20420110. |
therefore, the long-acting formulations of antipsychotics have been developed to improve the treatment compliance in patient with schizophrenia and risperidone long-acting injection (rlai) is the first long-acting injectable drug since then. |
2010-05-13 |
2023-08-12 |
Not clear |
| Magali Haas, Alan S Unis, Jorge Armenteros, Margaret D Copenhaver, Jorge A Quiroz, Stuart F Kushne. A 6-week, randomized, double-blind, placebo-controlled study of the efficacy and safety of risperidone in adolescents with schizophrenia. Journal of child and adolescent psychopharmacology. vol 19. issue 6. 2010-05-05. PMID:20035579. |
a 6-week, randomized, double-blind, placebo-controlled study of the efficacy and safety of risperidone in adolescents with schizophrenia. |
2010-05-05 |
2023-08-12 |
Not clear |
| Magali Haas, Alan S Unis, Jorge Armenteros, Margaret D Copenhaver, Jorge A Quiroz, Stuart F Kushne. A 6-week, randomized, double-blind, placebo-controlled study of the efficacy and safety of risperidone in adolescents with schizophrenia. Journal of child and adolescent psychopharmacology. vol 19. issue 6. 2010-05-05. PMID:20035579. |
the aim of this study was to evaluate the efficacy and safety of two dose ranges of risperidone in adolescents with schizophrenia. |
2010-05-05 |
2023-08-12 |
Not clear |
| Wayne Macfadden, Cynthia A Bossie, Ibrahim Turkoz, John Thomas Haskin. Risperidone long-acting therapy in stable patients with recently diagnosed schizophrenia. International clinical psychopharmacology. vol 25. issue 2. 2010-04-23. PMID:20101185. |
risperidone long-acting therapy in stable patients with recently diagnosed schizophrenia. |
2010-04-23 |
2023-08-12 |
Not clear |
| Ranganath D Rattehalli, Mahesh B Jayaram, Michael Smit. Risperidone versus placebo for schizophrenia. The Cochrane database of systematic reviews. issue 1. 2010-04-16. PMID:20091611. |
risperidone versus placebo for schizophrenia. |
2010-04-16 |
2023-08-12 |
Not clear |
| Seyed-Hesameddin Abbasi, Haleh Behpournia, Aboulfazl Ghoreshi, Bahman Salehi, Maedeh Raznahan, Shams-Ali Rezazadeh, Farzin Rezaei, Shahin Akhondzade. The effect of mirtazapine add on therapy to risperidone in the treatment of schizophrenia: a double-blind randomized placebo-controlled trial. Schizophrenia research. vol 116. issue 2-3. 2010-04-13. PMID:19959338. |
the effect of mirtazapine add on therapy to risperidone in the treatment of schizophrenia: a double-blind randomized placebo-controlled trial. |
2010-04-13 |
2023-08-12 |
human |
| Seyed-Hesameddin Abbasi, Haleh Behpournia, Aboulfazl Ghoreshi, Bahman Salehi, Maedeh Raznahan, Shams-Ali Rezazadeh, Farzin Rezaei, Shahin Akhondzade. The effect of mirtazapine add on therapy to risperidone in the treatment of schizophrenia: a double-blind randomized placebo-controlled trial. Schizophrenia research. vol 116. issue 2-3. 2010-04-13. PMID:19959338. |
this study was designed to investigate the effect of mirtazapine added to risperidone as augmentation therapy in patients with chronic schizophrenia and prominent negative symptoms in a double-blind and randomized clinical trial. |
2010-04-13 |
2023-08-12 |
human |
| Chuan Yuan Kang, Xiu Feng Xu, Zhen Yu Shi, Jian Zhong Yang, Hua Liu, Hong Hui X. Interaction of catechol-O-methyltransferase (COMT) Val108/158 Met genotype and risperidone treatment in Chinese Han patients with schizophrenia. Psychiatry research. vol 176. issue 1. 2010-04-12. PMID:20053459. |
interaction of catechol-o-methyltransferase (comt) val108/158 met genotype and risperidone treatment in chinese han patients with schizophrenia. |
2010-04-12 |
2023-08-12 |
Not clear |